HDAC6 and breast cancer: Consistent with this study’s findings, including demonstrated broad antiproliferative properties of C15:0 and phenotypic, mechanistic matching with two anti-cancer therapeutics, C15:0 has been recently shown to suppress breast cancer cells and inhibit dysregulation of histone deacetylase 6, a driver for epigenetic-based cancers [26, 29].